Paper · 40693603
Targeted therapies and immunotherapies for unresectable cholangiocarcinoma.
Xue S and 9 others. Chin Med J (Engl), 2025. Cited by 2 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Targeted therapies and immunotherapies for unresectable cholangiocarcinoma. Papers, record 40693603. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40693603
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cholangiocarcinoma | Major topic |
| Immunotherapy | Major topic |
| Bile Duct Neoplasms | Major topic |
| Molecular Targeted Therapy | Major topic |
| Humans |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References175
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32,464,280 | Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. | Ann Oncol | 2020 | https://conductscience.org/library/papers/32464280 | PubMed |
| 2 | 20,728,210 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. | Lancet | 2010 | https://conductscience.org/library/papers/20728210 | PubMed |
| 3 | 39,682,017 | Disease burden of biliary tract cancer in 204 countries and territories, 1990-2021: A comprehensive demographic analysis of the Global Burden of Disease Study 2021. | Chin Med J (Engl) | 2024 | https://conductscience.org/library/papers/39682017 | PubMed |
| 4 | 26,258,846 | Genomic spectra of biliary tract cancer. | Nat Genet | 2015 | https://conductscience.org/library/papers/26258846 | PubMed |
| 5 | 28,124,097 | Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. | Acta Neuropathol | 2017 | https://conductscience.org/library/papers/28124097 | PubMed |
| 6 | 22,176,869 | A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. | Eur J Cancer | 2012 | https://conductscience.org/library/papers/22176869 | PubMed |
| 7 | 32,416,072 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32416072 | PubMed |
| 8 | 35,544,727 | Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response. | JCO Precis Oncol | 2022 | https://conductscience.org/library/papers/35544727 | PubMed |
| 9 | 25,744,437 | BRAF V600E mutation-specific antibody: A review. | Semin Diagn Pathol | 2015 | https://conductscience.org/library/papers/25744437 | PubMed |
| 10 | 30,849,371 | VEGF in Signaling and Disease: Beyond Discovery and Development. | Cell | 2019 | https://conductscience.org/library/papers/30849371 | PubMed |
1 to 10 of 175
See all 175 referencesCited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,723,590 | Advances and challenges in immunotherapy for intrahepatic cholangiocarcinoma based on the tumour immune microenvironment. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42723590 | PubMed |
| 42,026,958 | [Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer]. | Korean J Gastroenterol | 2026 | https://conductscience.org/library/papers/42026958 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40693603
GET https://conductscience.org/api/papers/v1/40693603/references?page=2